489 related articles for article (PubMed ID: 30981205)
21. Long non‑coding RNA LUCAT1 contributes to cisplatin resistance by regulating the miR‑514a‑3p/ULK1 axis in human non‑small cell lung cancer.
Shen Q; Xu Z; Xu S
Int J Oncol; 2020 Oct; 57(4):967-979. PubMed ID: 32945379
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of miR-203 increases the sensitivity of NSCLC A549/H460 cell lines to cisplatin by targeting Dickkopf-1.
Cheng R; Lu C; Zhang G; Zhang G; Zhao G
Oncol Rep; 2017 Apr; 37(4):2129-2136. PubMed ID: 28350100
[TBL] [Abstract][Full Text] [Related]
23. Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J.
Shi L; Xu Z; Wu G; Chen X; Huang Y; Wang Y; Jiang W; Ke B
BMC Cancer; 2017 Feb; 17(1):138. PubMed ID: 28202053
[TBL] [Abstract][Full Text] [Related]
24. miR-181 regulates cisplatin-resistant non-small cell lung cancer via downregulation of autophagy through the PTEN/PI3K/AKT pathway.
Liu J; Xing Y; Rong L
Oncol Rep; 2018 Apr; 39(4):1631-1639. PubMed ID: 29484437
[TBL] [Abstract][Full Text] [Related]
25. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
[TBL] [Abstract][Full Text] [Related]
26. Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition.
Feng FF; Cheng P; Sun C; Wang H; Wang W
Chin J Nat Med; 2019 Oct; 17(10):768-777. PubMed ID: 31703757
[TBL] [Abstract][Full Text] [Related]
27. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
[TBL] [Abstract][Full Text] [Related]
28. Involvement of miR-4262 in paclitaxel resistance through the regulation of PTEN in non-small cell lung cancer.
Sun H; Zhou X; Bao Y; Xiong G; Cui Y; Zhou H
Open Biol; 2019 Jul; 9(7):180227. PubMed ID: 31337279
[TBL] [Abstract][Full Text] [Related]
29. Cisplatin resistance in lung cancer is mediated by MACC1 expression through PI3K/AKT signaling pathway activation.
Zhang Q; Zhang B; Sun L; Yan Q; Zhang Y; Zhang Z; Su Y; Wang C
Acta Biochim Biophys Sin (Shanghai); 2018 Aug; 50(8):748-756. PubMed ID: 29961813
[TBL] [Abstract][Full Text] [Related]
30. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9.
Rao C; Miao X; Zhao G; Zhang C; Shen H; Dong C; Yang M
Biomed Pharmacother; 2019 Jun; 114():108662. PubMed ID: 30999114
[TBL] [Abstract][Full Text] [Related]
31. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
[TBL] [Abstract][Full Text] [Related]
32. Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR.
Li B; Ding CM; Li YX; Peng JC; Geng N; Qin WW
Oncol Rep; 2018 Mar; 39(3):1227-1234. PubMed ID: 29344640
[TBL] [Abstract][Full Text] [Related]
33. miR-223 enhances the sensitivity of non-small cell lung cancer cells to erlotinib by targeting the insulin-like growth factor-1 receptor.
Zhao FY; Han J; Chen XW; Wang J; Wang XD; Sun JG; Chen ZT
Int J Mol Med; 2016 Jul; 38(1):183-91. PubMed ID: 27177336
[TBL] [Abstract][Full Text] [Related]
34. Exosomal miR-4443 promotes cisplatin resistance in non-small cell lung carcinoma by regulating FSP1 m6A modification-mediated ferroptosis.
Song Z; Jia G; Ma P; Cang S
Life Sci; 2021 Jul; 276():119399. PubMed ID: 33781830
[TBL] [Abstract][Full Text] [Related]
35. TRIM59 knockdown blocks cisplatin resistance in A549/DDP cells through regulating PTEN/AKT/HK2.
He R; Liu H
Gene; 2020 Jul; 747():144553. PubMed ID: 32165307
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-1 overexpression increases chemosensitivity of non-small cell lung cancer cells by inhibiting autophagy related 3-mediated autophagy.
Hua L; Zhu G; Wei J
Cell Biol Int; 2018 Sep; 42(9):1240-1249. PubMed ID: 29851226
[TBL] [Abstract][Full Text] [Related]
37. Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549).
Bian HB; Pan X; Yang JS; Wang ZX; De W
J Exp Clin Cancer Res; 2011 Feb; 30(1):20. PubMed ID: 21329503
[TBL] [Abstract][Full Text] [Related]
38. GAS5 knockdown reduces the chemo-sensitivity of non-small cell lung cancer (NSCLC) cell to cisplatin (DDP) through regulating miR-21/PTEN axis.
Cao L; Chen J; Ou B; Liu C; Zou Y; Chen Q
Biomed Pharmacother; 2017 Sep; 93():570-579. PubMed ID: 28686971
[TBL] [Abstract][Full Text] [Related]
39. Downregulation of miR-101 contributes to epithelial-mesenchymal transition in cisplatin resistance of NSCLC cells by targeting ROCK2.
Ye Z; Yin S; Su Z; Bai M; Zhang H; Hei Z; Cai S
Oncotarget; 2016 Jun; 7(25):37524-37535. PubMed ID: 27229528
[TBL] [Abstract][Full Text] [Related]
40. The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer.
Zhao J; Fu W; Liao H; Dai L; Jiang Z; Pan Y; Huang H; Mo Y; Li S; Yang G; Yin J
BMC Cancer; 2015 Oct; 15():731. PubMed ID: 26482648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
